ArticleHeliyon2024

An epidermal growth factor receptor-mutated lung adenocarcinoma patient with brain lesions resisted to osimertinib monotherapy but achieved more than 4 years of survival in osimertinib plus bevacizumab metronomic treatment.

Jie Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.